首页> 外文期刊>Modern Pathology >High prevalence of PIK3CA|[sol]|AKT pathway mutations in papillary neoplasms of the breast
【24h】

High prevalence of PIK3CA|[sol]|AKT pathway mutations in papillary neoplasms of the breast

机译:乳头状肿瘤中PIK3CA | [sol] | AKT途径突变的高发生率

获取原文
       

摘要

Papillary lesions of the breast have an uncertain relationship to the histogenesis of breast carcinoma, and are thus diagnostically and managerially challenging. Molecular genetic studies have provided evidence that ductal carcinoma in situ and even atypical ductal hyperplasia are precursors of invasive carcinoma. However, papillary lesions have been seldom studied. We screened papillary breast neoplasms for activating point mutations in PIK3CA, AKT1, and RAS protein-family members, which are common in invasive ductal carcinomas. DNA extracts were prepared from sections of 89 papillary lesions, including 61 benign papillomas (28 without significant hyperplasia; 33 with moderate to florid hyperplasia), 11 papillomas with atypical ductal hyperplasia, 7 papillomas with carcinoma in situ, and 10 papillary carcinomas. Extracts were screened for PIK3CA and AKT1 mutations using mass spectrometry; cases that were negative were further screened for mutations in AKT2, BRAF, CDK, EGFR, ERBB2, KRAS, NRAS, and HRAS. Mutations were confirmed by sequencing or HPLC assay. A total of 55 of 89 papillary neoplasms harbored mutations (62%), predominantly in AKT1 (E17K, 27 cases) and PIK3CA (exon 20 >exon 9, 27 cases). Papillomas had more mutations in AKT1 (54%) than in PIK3CA (21%), whereas papillomas with hyperplasia had more PIK3CA (42%) than AKT1 (15%) mutations, as did papillomas with atypical ductal hyperplasia (PIK3CA 45%, AKT1 27%, and NRAS 9%). Among seven papillomas with carcinoma in situ, three had AKT1 mutations. The 10 papillary carcinomas showed an overall lower frequency of mutations, including 1 with an AKT1 mutation (in a tumor arising from a papilloma), 1 with an NRAS gene mutation (Q61H), and 2 with PIK3CA mutations (1 overlapping with the NRAS Q61H). These findings indicate that approximately two-thirds of papillomas are driven by mutations in the PI3CA/AKT pathway. Some papillary carcinomas may arise from these lesions, but others may have different molecular origins.
机译:乳房的乳头状病变与乳腺癌的组织发生具有不确定的关系,因此在诊断和管理上具有挑战性。分子遗传学研究提供了证据,即原位导管癌甚至非典型导管增生是浸润性癌的前兆。然而,很少研究乳头状病变。我们筛选了乳头状乳腺肿瘤中PIK3CA,AKT1和RAS蛋白家族成员的激活点突变,这在浸润性导管癌中很常见。从89个乳头状病变的切片中提取DNA提取物,包括61个良性乳头状瘤(28个无明显增生; 33个中度至小花状增生),11个非典型导管增生的乳头状瘤,7个原位癌的乳头状瘤和10个乳头状癌。使用质谱法对提取物进行PIK3CA和AKT1突变筛选;阴性病例需进一步筛选AKT2,BRAF,CDK,EGFR,ERBB2,KRAS,NRAS和HRAS突变。通过测序或HPLC测定确认突变。 89个乳头状肿瘤中总共有55个具有突变(62%),主要在AKT1(E17K,27例)和PIK3CA(第20外显子>第9外显子,27例)中具有突变。乳头状瘤的AKT1突变(54%)比PIK3CA的突变(21%)多,而增生的乳头状瘤的PIK3CA(42%)比AKT1的突变(15%)多,非典型性导管增生的乳头瘤(PIK3CA) 45%,AKT1 27%和NRAS 9%)。在原位癌的七个乳头状瘤中,三个具有AKT1突变。这10个乳头状癌的总体突变频率较低,包括1个AKT1突变(在乳头状瘤引起的肿瘤中),1个NRAS基因突变(Q61H)和2个PIK3CA突变(1个与NRAS Q61H重叠) )。这些发现表明,大约三分之二的乳头状瘤是由PI3CA / AKT途径的突变驱动的。一些乳头状癌可能是由这些病变引起的,而另一些可能具有不同的分子起源。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号